Skip to main content
Figure 7 | BMC Pharmacology and Toxicology

Figure 7

From: A novel 11β-hydroxysteroid dehydrogenase type1 inhibitor CNX-010-49 improves hyperglycemia, lipid profile and reduces body weight in diet induced obese C57B6/J mice with a potential to provide cardio protective benefits

Figure 7

Effect of CNX-010-49 on lipid profile in DIO mice. Fasting serum TG levels (A) were monitored weekly. After the study termination, liver TG (B) was analyzed. Data in all panels are mean ± SEM (n = 8 mice/group). mRNA expression levels of liver CD36 and PPARα (C & D) were measured as mentioned in Methods. Statistical comparison was conducted by One-way ANOVA followed by Dunnett’s test or repeated measures ANOVA followed by Bonferroni correction (A) (n = 8 mice/group). Two-way repeated measures ANOVA indicated that CNX-010-49 significantly reduced the Fasting serum TG (p = 0.001; F = 1.865; Df = 20). (# - significance of HFD control against lean control, *- significance of CNX-010-49 treatment against HFD control) (*P < 0.05, **P < 0.01 and ***P < 0.001).

Back to article page